title: Hip circumference is associated with high density lipoprotein cholesterol response following statin therapy in hypertensive subjects.
abstract: OBJECTIVE
  This report investigated the relationship between anthropometric measurements of body fat distribution and lipid response to statins in hypercholesterolemic hypertensive patients.
  
  
  METHODS
  We prospectively examined 129 subjects who used either simvastatin 20 mg/day (no.=83) or atorvastatin 10 mg/day (no.=46) for 3 months. Anthropometry included evaluation of body mass index, waist and hip circumferences, and waist-to-hip-ratio.
  
  
  RESULTS
  Significant decreases in LDL (p<0.001), total cholesterol (p<0.001), and triglycerides (p=0.04) levels were detected after 3 months of therapy in the whole sample. At baseline, only an inverse correlation between waist circumference and HDLcholesterol levels was detected (r=-0.18; p=0.04). Conversely, a direct relationship between hip circumference and HDLcholesterol response to statins was found in the whole sample (r=0.24; p=0.006), while no other anthropometric measurement displayed significant correlation with lipid changes. The association between HDL-cholesterol response and hip circumference was further confirmed by stepwise regression analysis adjusted for baseline HDL-cholesterol levels, metabolic syndrome, body mass index, and waist circumference.
  
  
  CONCLUSIONS
  Hip circumference, a surrogate marker of peripheral adiposity, is associated with HDL-cholesterol changes following statin therapy in hypertensive patients.
authors.affiliation: Department of Internal Medicine, School of Medicine, University of Campinas, Campinas, Brazil.
authors.forename: J A
authors.initials: JA
authors.lastname: Pio-Magalhães
authors.forename: M C
authors.initials: MC
authors.lastname: Ferreira-Sae
authors.forename: F A
authors.initials: FA
authors.lastname: Souza
authors.forename: A M
authors.initials: AM
authors.lastname: Grespan-Magossi
authors.forename: R
authors.initials: R
authors.lastname: Schreiber
authors.forename: L A
authors.initials: LA
authors.lastname: Velloso
authors.forename: B
authors.initials: B
authors.lastname: Geloneze
authors.forename: K G
authors.initials: KG
authors.lastname: Franchini
authors.forename: W
authors.initials: W
authors.lastname: Nadruz
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use; D019821:Simvastatin / Q000627:therapeutic use; D055105:Waist Circumference; D049629:Waist-Hip Ratio
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin; D019821:Simvastatin